within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AA01_Methylphenobarbital;

model Methylphenobarbital
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.95,
    Cl = 7.777777777777777e-08,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0008,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Methylphenobarbital</td></tr><tr><td>ATC code:</td><td>N03AA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.004</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Methylphenobarbital is a barbiturate anticonvulsant, structurally related to phenobarbital, historically used in the treatment of epilepsy and seizure disorders. Its use has greatly declined and it is not widely approved or available in many countries today due to the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic data in humans are available from existing publications. Parameters estimated by analogy to phenobarbital and general barbiturate properties; assumed for healthy adults after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Methylphenobarbital;
